Kyverna Therapeutics, Inc. SEC filings KYTX
Kyverna Therapeutics, Inc. has 187 filings in SEC EDGAR's recent list, going back to Oct 5, 2023. Its latest annual report, Form ARS, was filed on Apr 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 24, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 24, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 27, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2026 | May 27, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
May 18, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
| 8-K |
Current report
Other events
|
May 4, 2026 | May 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 22, 2026 | Apr 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 22, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 20, 2026 | Apr 20, 2026 |
| ARS | Annual report to shareholders | Apr 13, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 13, 2026 | — |
| DEF 14A | Proxy statement | Apr 13, 2026 | May 27, 2026 |
| EFFECT | Filing | Apr 2, 2026 | — |
| 424B5 | Prospectus supplement | Apr 2, 2026 | — |
| CORRESP | Letter to the SEC | Mar 31, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 30, 2026 | — |
| S-8 | Employee stock plan registration | Mar 26, 2026 | — |
| S-3 | Shelf registration | Mar 26, 2026 | — |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 24, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 3, 2026 | Jan 29, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Jan 12, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 18, 2025 | Dec 17, 2025 |
| 424B5 | Prospectus supplement | Dec 18, 2025 | — |
| FWP | Free writing prospectus | Dec 17, 2025 | — |
| 424B5 | Prospectus supplement | Dec 15, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 15, 2025 | Dec 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 15, 2025 | Dec 15, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Nov 3, 2025 | Nov 2, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2025 | Oct 29, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2025 | Oct 29, 2025 |
| 8-K |
Current report
Officer or director change
|
Sep 25, 2025 | Sep 19, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Jun 30, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2025 | May 29, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| EFFECT | Filing | Apr 15, 2025 | — |
| 424B5 | Prospectus supplement | Apr 15, 2025 | — |
| ARS | Annual report to shareholders | Apr 14, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 14, 2025 | — |
| DEF 14A | Proxy statement | Apr 14, 2025 | May 29, 2025 |
| CORRESP | Letter to the SEC | Apr 11, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| 8-K |
Current report
Material agreement
|
Mar 27, 2025 | Mar 27, 2025 |
| S-8 | Employee stock plan registration | Mar 27, 2025 | — |
| S-3 | Shelf registration | Mar 27, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Other events
|
Jan 21, 2025 | Jan 21, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| S-8 | Employee stock plan registration | Nov 26, 2024 | — |
| 8-K |
Current report
Officer or director change
|
Nov 26, 2024 | Nov 26, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Nov 13, 2024 | Nov 8, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 21, 2024 | Oct 20, 2024 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 16, 2024 | Sep 13, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 15, 2024 | Jul 15, 2024 |
| UPLOAD | Letter from the SEC | Jul 11, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 14, 2024 | Jun 14, 2024 |
| 10-Q | Quarterly report | May 14, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2024 | Mar 26, 2024 |
| SEC STAFF LETTER | Filing | Feb 13, 2024 | — |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Feb 12, 2024 | Feb 12, 2024 |
| S-8 | Employee stock plan registration | Feb 8, 2024 | — |
| 424B4 | Prospectus | Feb 8, 2024 | — |
| CERT | Filing | Feb 8, 2024 | — |
| EFFECT | Filing | Feb 7, 2024 | — |
| S-1/A | Amended registration statement | Feb 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| CORRESP | Letter to the SEC | Feb 5, 2024 | — |
| 8-A12B | Filing | Feb 5, 2024 | — |
| S-1/A | Amended registration statement | Feb 1, 2024 | — |
| CORRESP | Letter to the SEC | Jan 25, 2024 | — |
| CORRESP | Letter to the SEC | Jan 16, 2024 | — |
| S-1 | Registration statement | Jan 16, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 10, 2024 | — |
| DRS/A | Filing | Jan 8, 2024 | — |
| DRSLTR | Filing | Jan 5, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 28, 2023 | — |
| SEC STAFF LETTER | Filing | Dec 15, 2023 | — |
| DRSLTR | Filing | Dec 13, 2023 | — |
| DRS/A | Filing | Dec 13, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2023 | — |
| DRSLTR | Filing | Nov 9, 2023 | — |
| DRS/A | Filing | Nov 9, 2023 | — |
| D | Filing | Nov 7, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2023 | — |
| DRS | Filing | Oct 5, 2023 | — |
Showing 101 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1994702
- Former names
- Kyverna Therapeutics, Inc. (until Oct 19, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.